Efficacy and Safety of Bovhyaluronidase Azoximer (Longidaza) in Patients with Post-COVID-19 Syndrome: Results of the Open-label Prospective Controlled Comparative Multicenter Clinical Trial Dissolve
1.1. Introduction: Post-COVID-19 syndrome is a condition that develops in the patients recovered from COVID-19 resulting into the cumulative effects of dyspnoea and impaired lung function. Notably, higher concentrations of HA have been found in patients with respiratory inflammation and COVID-19. As, bovhyaluroni dase azoximer (Longidaza®) catalyses the hydrolysis of HA, the treatment has the […]